Twin Focus Capital Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Twin Focus Capital Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,000	Closed	-$59K	–	96
2016 Q3	$59K	Hold	10,000	–	–	0.04%	88
2016 Q2	$30K	Buy	+10,000	New	+$41.1K	0.02%	82

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Twin Focus Capital Partners's DRNA Position: Q4 2016 in Review

Twin Focus Capital Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2016, closing a stake of 10,000 shares — an estimated $59K sold.

Twin Focus Capital Partners first reported a position in DRNA in Q2 2016 and held it in 2 quarters. The position peaked at $59K in Q3 2016. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

Twin Focus Capital Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Twin Focus Capital Partners sold 10,000 Dicerna Pharmaceuticals, Inc. shares in Q4 2016, an estimated $59K.
Twin Focus Capital Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
Twin Focus Capital Partners's Dicerna Pharmaceuticals, Inc. position peaked at $59K in Q3 2016.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on Twin Focus Capital Partners's 13F filing for Q4 2016, filed 10 Feb 2017.